Core Viewpoint - The strategic partnership between Kefu Medical, Wisdom Eye Technology, and Laolai Health aims to create an innovative healthcare service ecosystem by integrating AI technology, smart hardware, and internet platforms to enhance the accessibility and personalization of medical services [1][2]. Group 1: Partnership Objectives - The collaboration focuses on leveraging each company's strengths in AI technology, smart hardware development, and internet platform operations to build a closed-loop health management solution [1][2]. - The partnership intends to enhance the integration of cutting-edge technology, smart devices, and user platforms to provide comprehensive health management solutions for patients [1]. Group 2: Technological Integration - Wisdom Eye will utilize its AI technology to develop a medical model and algorithms for disease risk prediction, personal health profiling, and auxiliary diagnosis [1][2]. - Kefu Medical will provide access to its portable smart medical devices, ensuring seamless data interaction between devices and AI models for efficient data flow [1][2]. - Laolai Health will contribute its extensive user data from over 200 million elderly users to improve the accuracy and applicability of AI models [1][2]. Group 3: Product Development - The three companies will jointly develop next-generation AI-driven portable and home medical devices focusing on real-time monitoring of chronic disease indicators, personalized intervention plans, and emergency alerts for critical health conditions [2]. - The collaboration aims to create a complete health management service chain that integrates monitoring, analysis, intervention, and follow-up through the Laolai Health platform [2]. Group 4: Industry Impact - This partnership is expected to address industry challenges such as uneven distribution of medical resources and difficulties in chronic disease management, providing higher quality and more accessible healthcare services to a broader population, particularly for home care and chronic disease patients [3]. - The collaboration signifies a shift in the healthcare industry from fragmented services to an integrated and intelligent new ecosystem [3].

Company Overview - Cofoe Medical Technology Co., Ltd. specializes in the research, production, sales, and service of medical devices, with key products including blood glucose systems, uric acid systems, blood pressure monitors, and various other medical instruments and supplies [2]. Financial Performance - For Q1 2025, the company reported revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.43 million yuan, down 9.68%, with a gross profit margin of 52.17% [2]. Market Position - As of June 10, Cofoe Medical's stock closed at 34.26 yuan, up 4.26%, with a rolling price-to-earnings (PE) ratio of 23.72, marking a new low in 44 days. The company's total market capitalization is 7.163 billion yuan [1]. - In comparison to the medical device industry, which has an average PE of 51.00 and a median of 37.03, Cofoe Medical ranks 50th in terms of PE [1][3]. Shareholder Information - As of April 10, 2025, Cofoe Medical had 18,000 shareholders, a decrease of 428 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].

Company Overview - Cofoe Medical Technology Co., Ltd. specializes in the research, production, sales, and service of medical devices, with key products including blood glucose systems, uric acid systems, blood pressure monitors, and various other medical instruments and supplies [2]. Financial Performance - For Q1 2025, the company reported a revenue of 738 million yuan, representing a year-on-year decrease of 8.59%. The net profit was 91.43 million yuan, down 9.68% year-on-year, with a gross profit margin of 52.17% [2]. Market Position - As of May 29, Cofoe Medical's stock closed at 34.01 yuan, up 2.97%, with a rolling price-to-earnings (PE) ratio of 23.55, marking a new low in 37 days. The company's total market capitalization is 7.111 billion yuan [1]. - In comparison to the medical device industry, which has an average PE of 49.64 and a median of 36.36, Cofoe Medical ranks 50th in terms of PE [1][3]. Shareholder Information - As of April 10, 2025, Cofoe Medical had 18,000 shareholders, a decrease of 428 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].

Group 1 - The core viewpoint of the article highlights the launch of the "Yuan Benshu" brand by Kefu Medical, focusing on innovative medical dressings and skin repair products to drive high-quality development in the industry [1][3] - Kefu Medical emphasizes that "Yuan Benshu" is not a face mask but a medical dressing, aiming to provide safer and more effective skin repair solutions based on nearly 20 years of medical research and development [3][5] - The brand's name "ibssom," meaning "to bloom," reflects a commitment to women's health and confidence, with a product matrix covering various application methods [5] Group 2 - Three innovative products were launched at the event: the upgraded "Little Blue Mask 3.0," a liquid collagen dressing, and the "White Ice Cannon" strong pulsed light therapy device [1][7] - The "Little Blue Mask 3.0" features an improved formulation with upgraded hyaluronic acid content and added natto essence, enhancing its moisturizing and repairing effects [5][7] - The liquid collagen dressing offers 100% human-derived collagen and utilizes advanced structural technology to improve skin elasticity and reduce signs of aging [7][9] Group 3 - The "White Ice Cannon" device combines medical equipment with medical dressings, showing significant clinical results, including a 94.31% reduction in hair density and a 26.28% decrease in skin roughness after four weeks of use [7][9] - Experts noted that the medical beauty market has surpassed 300 billion yuan, with increasing consumer demand for safe and effective skin repair products, positioning Yuan Benshu's new offerings as solutions to industry pain points [9]

证券代码：301087 证券简称：可孚医疗 公告编号：2025-039 可孚医疗科技股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、可孚医疗科技股份有限公司（以下简称"公司"）回购专用证券账户中 的股份 5,699,731 股不参与本次权益分派。本次权益分派将以公司目前总股本 209,092,000 股扣除公司回购专用证券账户中已回购股份 5,699,731 股后的总股本 203,392,269 股为基数，向全体股东每 10 股派发现金红利 12 元（含税），实际 派发现金分红总额（含税）=203,392,269 股×12 元÷10 股=244,070,722.80 元， 不送红股，不以资本公积金转增股本。 2、本次实施权益分派后，按公司总股本（含回购股份）折算每 10 股现金分 红金额=本次实际现金分红总额（含税）÷公司总股本（含回购股份）×10 股 =244,070,722.80 元÷209,092,000 股×10 股=11.672886 元(保留六位小数，不四舍 五入)，即每股现金分红（含税 ...

证券代码：301087 证券简称：可孚医疗 公告编号：2025-036 可孚医疗科技股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 可孚医疗科技股份有限公司（以下简称"公司"或"可孚医疗"）于 2025 年 4 月 25 日召开第二届董事会第十四次会议、第二届监事会第十四次会议，审 议通过了《关于公司及子公司向银行申请综合授信及公司为子公司提供担保的议 案》，根据公司发展计划，为满足公司日常经营及业务结算的需要，提高资金使 用效率，公司及子公司拟向银行申请不超过人民币 13 亿元的综合授信额度，综 合授信品种包括但不限于：流动资金贷款、中长期借款、银行承兑汇票、保函、 信用证、抵押贷款等。在授信有效期限内，授信额度可循环使用。公司为全资子 公司申请的银行授信额度内的融资提供担保，担保总额不高于人民币 9 亿元。该 事项自董事会通过之日起十二个月内有效，董事会授权公司法定代表人或法定代 表人指定的授权代理人根据实际经营情况需要，在总额度内办理公司及子公司的 融资和担保事宜，具体内容详见公司刊登于巨潮 ...

证券代码：301087 证券简称：可孚医疗 公告编号：2025-037 可孚医疗科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东大会未出现否决议案的情形。 2. 本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1. 会议召开时间： （1）现场会议召开时间：2025年5月21日（星期三）14:30； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025年5月21日的交易时间，即9:15 - 9:25，9:30 - 11:30和13:00 - 15:00；通过深 圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间为： 2025年5月21日9:15 - 15:00。 2. 现场会议召开地点：长沙市雨花区万家丽中路一段426号高桥大健康医药 城8楼801会议室。 3. 会议召开方式：采取现场投票与网络投票相结合的方式。 4. 会议召集人：公司董事会。 出席本次会议的股东及股东代表共125人，代表有表 ...

湖南启元律师事务所 关于可孚医疗科技股份有限公司 2024年年度股东大会的 法律意见书 二0二五年五月 湖南启元律师事务所 1、刊登在深圳证券交易所网站（https://www.szse.cn/）的与本次股东大会有 关的通知等公告事项； 关于可孚医疗科技股份有限公司 2024 年年度股东大会的法律意见书 致：可孚医疗科技股份有限公司 湖南启元律师事务所接受可孚医疗科技股份有限公司（以下简称"公司"）的 委托，指派律师出席了公司 2024 年年度股东大会（以下简称"本次股东大会"）， 对本次股东大会的召集和召开程序、出席会议人员及召集人的资格、表决程序和 表决结果的合法有效性进行现场律师见证，并发表本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》（以 下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《可孚医 疗科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定出具本法 律意见书。 本所律师声明如下： （一）本所律师根据本法律意见书出具日以前已经发生或者存在的事实，严 格履行了法定职责，遵 ...

证券代码：301087 证券简称：可孚医疗 公告编号：2025-038 可孚医疗科技股份有限公司 关于回购注销部分限制性股票通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 可孚医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 第二届董事会第十四次会议和第二届监事会第十四次会议，审议通过了《关于回 购注销部分限制性股票的议案》。 根据公司《2021 年限制性股票激励计划（草案）》《2021 年限制性股票激 励计划实施考核管理办法》等相关规定，鉴于公司 2024 年度未达到业绩考核目 标，第一类限制性股票第三个限售期对应的 19.50 万股限制性股票不得解除限售， 董事会审议决定回购注销上述 19.50 万股限制性股票。本次回购注销完成后，公 司总股本将由 209,092,000 股减至 208,897,000 股，公司注册资本也相应由 209,092,000 元减少为 208,897,000 元。 公司本次回购注销部分限制性股票将导致注册资本减少，根据《中华人民共 和国公司法》等相关法律法规的规定，公司特此通知债权 ...

证券研究报告：医药生物 | 公司点评报告 发布时间：2025-05-21 股票投资评级 买入|首次覆盖 个股表现 -24% -20% -16% -12% -8% -4% 0% 4% 8% 12% 2024-05 2024-07 2024-10 2024-12 2025-03 2025-05 可孚医疗 医药生物 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 32.97 | | --- | --- | | 总股本/流通股本（亿股）2.09 / 1.94 | | | 总市值/流通市值（亿元）69 / 64 | | | 52 周内最高/最低价 | 43.40 / 28.90 | | 资产负债率(%) | 25.2% | | 市盈率 | 21.55 | | 第一大股东 | 长沙械字号医疗投资有 | | 限公司 | | 研究所 分析师:蔡明子 SAC 登记编号:S1340523110001 Email:caimingzi@cnpsec.com 研究助理:陈峻 SAC 登记编号:S1340123110013 Email:chenjun@cnpsec.com 可孚医疗(301087) 康复辅具类产品 ...